ReportWire

Tag: Clinical Trials

  • WTOP’s Neal Augenstein: 3 years after Stage 4 lung cancer diagnosis, what’s next – WTOP News

    [ad_1]

    During the first three years of Augenstein’s lung cancer journey, he’s been happy to be able to share things he has been learning along the way.

    WTOP’s Neal Augenstein was diagnosed with Stage 4 lung cancer in 2022. (WTOP/Neal Augenstein)

    In my first 25 years at WTOP, my reports about lung cancer were primarily stories about famous people who died from the deadliest and second-most common cancer in the U.S. — until I was diagnosed with Stage 4 lung cancer exactly three years ago.

    Since then, most of my lung cancer stories have been about living.

    Within six months of being diagnosed with Stage 4 non-small cell lung cancer just before Thanksgiving 2022, after great results with one-pill-a-day targeted therapy that shrank cancerous tumors and lymph nodes in both lungs, I became eligible for a robotic-assisted lung lobectomy.

    Since then, I’ve had no evidence of disease, and have remained cancer-free since May 2023, while continuing to take my daily pill.

    Giving thanks? Indeed.

    During the first three years of my journey, I’ve been happy to be able to share things I’ve been learning along the way.

    First, is the importance of newly diagnosed cancer patients getting biomarker testing, and waiting for the results before beginning treatment.

    Biomarker testing involves testing biopsied lung tissue — often taken during a bronchoscopy — to try to learn the exact cell mutation that caused a patient’s cancer.

    “The importance of testing is if they have that mutation, then the treatment is very different, and the patient outcomes are also much better,” thoracic medical oncologist Ram Subramanian with Inova Schar Cancer Institute in Fairfax County, Virginia, told me.

    In my case, I was diagnosed with EGFR-positive lung cancer, which has several targeted treatments available, and generally limits the side effects of treatment compared to chemotherapy.

    Despite having no evidence of cancer now, I (and my doctors) wouldn’t say that I’m “cured,” since I was originally diagnosed after cancer had spread from the original site in my left lung.

    In 2025, life with lung cancer can be similar to life with other chronic diseases, including diabetes or heart disease.

    The key is aggressive surveillance, which in my case involves low-dose CT scans every four months, as well as brain MRIs and liquid biopsies twice a year. If something suspicious were to show up on one of these scans, it would likely be early-stage, which could be removed with surgery or targeted by radiation.

    And, while the  American Lung Association’s 2025 State of Lung Cancer report shows the five-year survival rate for lung cancer in the U.S. has risen to 29.7%, which represents a 26% improvement over the past five years, research continues to enable earlier detection, including the use of artificial intelligence.

    Lung cancer patients in the D.C. region are lucky — there are a large number of clinical trials in Virginia, Maryland and the District, offering new options and hope for patients and their families.

    Personally, while I’ve been lucky to not have any recurrences in my first three years living with cancer, I often discuss trials with my thoracic oncologist Amin Benyounes, who is the co-leader at the Inova Schar Cancer Institute’s Phase One Program.

    Benyounes said many patients considering enrollment in a clinical trial worry about the unknown: “Will this make me feel worse, will it make me feel sick, could it hurt more than it would help? Will my kids or my partner have to bear the burden of me feeling sick?”

    With clinical trials affording the possibilities for longer survival with fewer side effects, some patients ask, “What if I get my hopes up, and it doesn’t work?”

    According to Benyounes: “My answer to that is usually, ‘We have to take things one step at a time.’”

    That’s the same guidance he gave me when I began my cancer journey, three years ago.

    Get breaking news and daily headlines delivered to your email inbox by signing up here.

    © 2025 WTOP. All Rights Reserved. This website is not intended for users located within the European Economic Area.

    [ad_2]

    Neal Augenstein

    Source link

  • Stony Brook Medicine launches clinical trials unit in Commack | Long Island Business News

    [ad_1]

    THE BLUEPRINT:

    • 6,000 sq. ft. Unit now open at

    • Features 12 exam rooms, infusion bays, and specialized testing labs

    • Supports trials for all ages

    opened its 6,000-square-foot Clinical Trials Unit at the Advanced Specialty Care at Commack center. Celebrated with a ribbon-cutting on Monday, the unit provides patients with a chance to take part in advanced therapeutic studies and offers physicians and researchers a shared space to conduct clinical trials.

    The space expands Stony Brook’s capacity and research infrastructure to support scientifically rigorous clinical trials that integrate discovery and development to explore new treatments and improve patient outcomes. The facility accommodates trial participants across the lifespan, including children, older adults and individuals with physical disabilities.

    “As we cut the ribbon on this new Clinical Trials Unit here in Commack, we’re celebrating the opening of a new facility, but more importantly, we’re opening doors to discovery and to hope,” Dr. William Wertheim, executive vice president of Stony Brook Medicine, said in a news release about the unit.

    The unit includes 12 examination and consultation rooms, a cardiopulmonary exercise testing facility and a physical performance and gait testing suite. It also features a three-bay infusion area for trials involving chemotherapeutic and intravenous infusions, a procedure room for outpatient trials and a wet lab equipped with a refrigerated centrifuge and a minus-80 F freezer for processing blood and other human samples.

    “This space represents the bridge between groundbreaking research in the laboratory and the patients and families we serve every day, right here in our communities,” Wertheim said.

    The new unit is designed to make advanced clinical trials more accessible to the people served by the system.

    “For decades, Stony Brook Medicine has been known for translating research from bench to bedside,” Wertheim said. “With this new unit, for the first time, we’re extending that promise beyond the hospital, bringing access to advanced clinical trials closer to where people live and work. It’s a tangible example of how we’re strengthening our connection to the community and ensuring that participation in world-class research is not limited by distance or circumstance.”

    Dr. Peter Igarashi, the dean of the Renaissance School of Medicine at Stony Brook University, shared that sentiment.

    “Academic medicine brings added value in the form of expertise of our academic faculty clinicians, as well as access to state-of-the-art technologies and access to clinical trials, and that’s why we have built this facility,” Igarashi said in the news release. “We look forward to the exciting discoveries that will emerge from the research program for years to come.”

    Now fully operational, the unit is staffed with specialists and principal investigators to manage trials from planning to execution. The unit will conduct studies on a range of conditions, including neurological, cardiovascular, pulmonary, kidney, cancer, mental health and infectious diseases.

    “Currently, we have 260 active clinical trials,” Dr. Susan Hedayati, vice dean for research in the Renaissance School of Medicine at Stony Brook University, said in the news release.

    “These trials account for a vast majority of all of the clinical trials within SUNY academic institutions,” Hedayati added. “By building this Commack Clinical Trials Unit, we’re very enthusiastic that we will have the capacity to significantly and substantially increase this number.”


    [ad_2]

    Adina Genn

    Source link

  • There are more than 100 autoimmune diseases, and they mostly strike women. Here’s what to know

    [ad_1]

    Our immune system has a dark side: It’s supposed to fight off invaders to keep us healthy. But sometimes it turns traitor and attacks our own cells and tissues.

    What are called autoimmune diseases can affect just about every part of the body – and tens of millions of people. While most common in women, these diseases can strike anyone, adults or children, and they’re on the rise.

    New research is raising the prospect of treatments that might do more than tamp down symptoms. Dozens of clinical trials are testing ways to reprogram an immune system-gone-rogue, with some promising early successes against lupus, myositis and certain other illnesses. Other researchers are hunting ways to at least delay brewing autoimmune diseases, spurred by a drug that can buy some time before people show symptoms of Type 1 diabetes.

    “This is probably the most exciting time that we’ve ever had to be in autoimmunity,” said Dr. Amit Saxena, a rheumatologist at NYU Langone Health.

    Here are some things to know.

    What are autoimmune diseases?

    They’re chronic diseases that can range from mild to life-threatening, more than 100 with different names depending on how and where they do damage. Rheumatoid arthritis and psoriatic arthritis attack joints. Sjögren’s disease is known for dry eyes and mouth. Myositis and myasthenia gravis weaken muscles in different ways, the latter by attacking how nerves signal them. Lupus has widely varied symptoms including a butterfly-shaped facial rash, joint and muscle pain, fevers and damage to the kidneys, lungs and heart.

    They’re also capricious: Even patients faring well for long periods can suddenly have a “flare” for no apparent reason.

    Why autoimmune diseases are so difficult to diagnose

    Many start with vague symptoms that come and go or mimic other illnesses. Many also have overlapping symptoms – rheumatoid arthritis and Sjögren’s also can harm major organs, for example.

    Diagnosis can take multiple tests, including some blood tests to detect antibodies that mistakenly latch onto healthy tissue. It usually centers on symptoms and involves ruling out other causes. Depending on the disease it can take years and seeing multiple doctors before one puts the clues together. There are efforts to improve: The National MS Society is educating doctors about newly updated guidelines to streamline diagnosis of multiple sclerosis.

    How the immune system gets out of whack

    The human immune system is a complex army with sentinels to detect threats like germs or cancer cells, a variety of soldiers to attack them, and peacemakers to calm things down once the danger is over. Key is that it can distinguish what’s foreign from what’s “you,” what scientists call tolerance.

    Sometimes confused immune cells or antibodies slip through, or the peacemakers can’t calm things down after a battle. If the system can’t spot and fix the problem, autoimmune diseases gradually develop.

    Autoimmune diseases are often set off by a trigger

    Most autoimmune diseases, especially in adults, aren’t caused by a specific gene defect. Instead, a variety of genes that affect immune functions can make people susceptible. Scientists say it then takes some “environmental” trigger, such as an infection, smoking or pollutants, to set the disease into motion. For example, the Epstein-Barr virus is linked to MS.

    Scientists are zeroing in on the earliest molecular triggers. For example, white blood cells called neutrophils are first responders to signs of infection or injury — but abnormally overactive ones are suspected of playing a key role in lupus, rheumatoid arthritis and other diseases.

    Women are at highest risk for autoimmune diseases

    Women account for about 4 of 5 autoimmune patients, many of them young. Hormones are thought to play a role. But also, females have two X chromosomes while males have one X and one Y. Some research suggests an abnormality in how female cells switch off that extra X can increase women’s vulnerability.

    But men do suffer from autoimmune diseases. One especially severe one named VEXAS syndrome wasn’t discovered until 2020. It mainly affects men over 50 and in addition to typical autoimmune symptoms it can cause blood clots, shortness of breath and night sweats.

    Certain populations also have higher risks. For example, lupus is more common in Black and Hispanic women. Northern Europeans have a higher risk of MS than other groups.

    Treatment for autoimmune diseases is complicated

    According to investment research company Morningstar, the global market for autoimmune disease treatments is $100 billion a year. That’s not counting doctor visits and such things as lost time at work. Treatment is lifelong and, while usually covered by insurance, can be pricey.

    Not so long ago there was little to offer for many autoimmune diseases beyond high-dose steroids and broad immune-suppressing drugs, with side effects that include a risk of infections and cancer. Today some newer options target specific molecules, somewhat less immune dampening. But for many autoimmune diseases, treatment is trial and error, with little to guide patient decisions.

    ___

    The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.

    [ad_2]

    Source link

  • Northwell opens a $14M women’s cancer center in New Hyde Park | Long Island Business News

    [ad_1]

    New Hyde Park is now home to a $14 million, 21,000-square-foot for women.

    Northwell Cancer Institute’s Center for Women’s Cancer at the R.J. Zuckerberg Cancer Center offers comprehensive breast and gynecological cancer services. The new facility is designed to provide specialized, integrated care through all stages of treatment and long-term follow-up, and in one location, easing logistical travel burdens.

    The center aims to close a gap in cancer care for women by aligning breast and gynecologic oncology services to incorporate shared genetic and clinical characteristics, particularly in patients with variants and other hereditary cancers.

    “This new center represents our commitment to and the recognition that women’s cancers require specialized, coordinated care,” Dr. Richard Barakat, physician-in-chief and executive director of the Northwell Cancer Institute, said in a news release about the center.

    “By unifying our expertise in breast and gynecologic malignancies, we’re not just enhancing convenience — we’re creating a new approach where genetic counseling, surgical intervention, medical therapy and psychosocial support come together seamlessly, ultimately improving survival rates and quality of life for our patients,” Barakat said.

    The center opens at a time when there are about 311,000 new invasive cases and 117,000 new cases each year in the United States, according to estimates released in 2024 by the American Cancer Society.

    By integrating breast surgery, gynecologic oncology, medical oncology and comprehensive support services, the center aims to address the interconnected nature of women’s cancer risks, offering care tailored to women’s specific health needs.

    Designed by Boston-based E4H Architecture, the center features 26 exam rooms, 10 consultation rooms, two procedure rooms, an onsite laboratory and a therapeutic garden designed to promote relaxation and support wellness. Accessible services include infusion therapy, radiation medicine, plastic surgery, genetic counseling, genomic testing, imaging and – all of which are steps away within the same building.

    The center links the Northwell Cancer Institute and the health system’s Katz Institute for Women’s Health. More than 20 physicians and multidisciplinary teams will collaborate daily, according to established clinical practices that enable real-time care planning and accelerated treatment protocols.

    “The center makes it easier for us to develop care plans with our colleagues and manage our patients as one team,” Dr. Veena John, system head for gynecologic medical oncology at the Northwell Cancer Institute and medical director for the Center for Women’s Cancer, said in the news release.

    “Whether it is a medical oncology trial, a radiation medicine trial or a surgical trial, they will all be available to patients in the same building, limiting the need to go to different sites to enroll,” John added. “Particularly for patients with recurrent disease, we have ongoing trials that offer unique therapies that are otherwise not available, and we expect that the number of trial opportunities will continue to grow.”

    Nurse navigators can coordinate care and guide patients through consultation, treatment and survivorship. Navigators collectively speak nine languages, including Armenian, Cantonese, Hindi and Spanish.


    [ad_2]

    Adina Genn

    Source link

  • Trump’s touting of an unproven autism drug surprised many, including the doctor who proposed it

    [ad_1]

    When President Donald Trump’s administration announced it would repurpose an old, generic drug as a new treatment for autism, it came as a surprise to many experts — including the physician who suggested the idea to the nation’s top health officials.Dr. Richard Frye told The Associated Press that he’d been talking with federal regulators about developing his own customized version of the drug for children with autism, assuming more research would be required.”So we were kinda surprised that they were just approving it right out of the gate without more studies or anything,” said Frye, an Arizona-based child neurologist who has a book and online education business focused on the experimental treatment.It’s another example of the quick rollout of the Trump administration’s Monday announcement on autism, which critics say has elevated an unproven drug that needs far more study before being approved as a credible treatment for the complex brain disorder.A spokesperson for the Republican administration did not immediately respond to a request for comment Wednesday morning.The nation’s leading autism groups and researchers quickly distanced themselves from the decision on leucovorin, a derivative of vitamin B, calling the studies supporting its use “very weak” and “very small.””We have nothing resembling even moderate evidence that leucovorin is an effective treatment for autism symptoms,” said David Mandell, a psychiatrist at the University of Pennsylvania.Mandell and other researchers say the evidence suggests autism is mostly rooted in genetics, with input from other factors, including the age of the child’s father.Nevertheless, a growing number of doctors are prescribing the medication, repurposing versions used for chemotherapy or ordering new formulations from compounding pharmacies.Many researchers agree the drug warrants additional study, particularly for patients with a deficiency of folate, or vitamin B9, in the brain that may play a role in autism. But for now, they say, it should only be taken in carefully controlled clinical trials.”We often say our job is to stay between the yellow lines,” said Dr. Lawrence Gray, a pediatric developmental specialist at Northwestern University. “When people just decide to go outside of current guidelines, then they’re outside of that. And nobody knows what’s going to happen out there.”Related video below: Parents, doctors react to Trump administration claims about Tylenol and autismThe evidence for leucovorin isn’t settledThe case for leucovorin’s use in autism begins with established science but quickly veers into uncertain terrain.When metabolized, the drug turns into folate, which is essential for healthy prenatal development and is recommended before and during pregnancy. But far less is known about its role after birth.The issue caught the attention of Frye and others more than 20 years ago, when research suggested some people with autism had low levels of folate in the brain due to antibodies blocking the vitamin’s absorption.The theory linking autism to folate levels was mostly abandoned, however, after research showed that the siblings of people with autism can also have low folates without any symptoms of the condition.”I honestly thought this had died out as a theory for autism and was shocked to see its reemergence,” Mandell said.In 2018, Frye and his colleagues published a study of 48 children in which those taking leucovorin performed better on several language measures than those taking a placebo.Four small studies in other countries, including China and Iran, showed similar results, albeit using different doses, metrics and statistical analyses, which researchers say is problematic.Frye struggled to get funding to continue within the traditional academic system.”I decided to move out of academia to be more innovative and actually do some of this stuff,” he said.Researchers saw an opening to approach Trump’s top health officialsEarlier this year, Frye and several other researchers formed a new entity, the Autism Discovery Coalition, to pitch their work to Trump administration officials including Health Secretary Robert F. Kennedy Jr.”After Kennedy got in, we thought they’d hopefully be friendly to autism scientists,” he said.An August meeting with National Institutes of Health Director Jay Bhattacharya quickly led to further discussions with the Food and Drug Administration about testing a proprietary, purified version of leucovorin.A new formulation of the decades-old drug would mean new patents, allowing Frye and his yet-to-be-formed drug company to charge far more than the cheap generics currently on the market.”We have a lot of investors who are excited about leucovorin and want to do something high quality for kids with autism,” he said.But the FDA’s announcement Monday may have scuttled that plan. Instead of previewing a new version, the agency said it would simply update the label on the generic drug to mention use in boosting folate brain levels, including for patients with autism. That’s expected to encourage more doctors to prescribe it and insurers to cover it.Promising autism treatments often fail after more studySpecialists who have spent decades treating autistic patients say it’s important to proceed carefully.Gray recalls other experimental treatments that initially looked promising only to fail in larger studies.”Small studies often find populations that are very motivated,” Gray said. “But when those therapies are moved into larger studies, the initial positive findings often disappear.”Among the challenges facing leucovorin: There isn’t agreement about what portion of autism patients have the folate-blocking antibodies supposedly targeted by the drug.Frye screens his patients for the antibodies using a test developed at a laboratory at the State University of New York. Like many specialty tests, it has not been reviewed by the FDA.Gray says the only way to definitively test for the antibodies would be by extracting cranial fluid from children with autism through a spinal tap.”That’s a big limiting factor in having these large, randomized controlled trials,” Gray said.Related video below: Get the Facts on the White House’s claims linking Tylenol and autismOnline sources are driving interest from parentsWhile the Trump administration discusses fast-tracking leucovorin, interest in the drug continues to swirl online, including in forums and social media groups for parents of children with autism.Brian Noonan, of Phoenix, found out about the drug earlier this year after asking ChatGPT for the best autism drug options for his 4-year-old son.The FDA has never approved any drug for the underlying causes of autism, but the chatbot directed Noonan to Frye’s research.After an evaluation and confirmatory blood test, the boy started on a formulation of the drug from a compounding pharmacy in June.Within days, Noonan says, he saw improvement in his son’s ability to make eye contact and form sentences.”He’s not cured, but these are just areas of improvement,” Noonan said. “It’s been a big thing for us.”

    When President Donald Trump’s administration announced it would repurpose an old, generic drug as a new treatment for autism, it came as a surprise to many experts — including the physician who suggested the idea to the nation’s top health officials.

    Dr. Richard Frye told The Associated Press that he’d been talking with federal regulators about developing his own customized version of the drug for children with autism, assuming more research would be required.

    “So we were kinda surprised that they were just approving it right out of the gate without more studies or anything,” said Frye, an Arizona-based child neurologist who has a book and online education business focused on the experimental treatment.

    It’s another example of the quick rollout of the Trump administration’s Monday announcement on autism, which critics say has elevated an unproven drug that needs far more study before being approved as a credible treatment for the complex brain disorder.

    A spokesperson for the Republican administration did not immediately respond to a request for comment Wednesday morning.

    The nation’s leading autism groups and researchers quickly distanced themselves from the decision on leucovorin, a derivative of vitamin B, calling the studies supporting its use “very weak” and “very small.”

    “We have nothing resembling even moderate evidence that leucovorin is an effective treatment for autism symptoms,” said David Mandell, a psychiatrist at the University of Pennsylvania.

    Mandell and other researchers say the evidence suggests autism is mostly rooted in genetics, with input from other factors, including the age of the child’s father.

    Nevertheless, a growing number of doctors are prescribing the medication, repurposing versions used for chemotherapy or ordering new formulations from compounding pharmacies.

    Many researchers agree the drug warrants additional study, particularly for patients with a deficiency of folate, or vitamin B9, in the brain that may play a role in autism. But for now, they say, it should only be taken in carefully controlled clinical trials.

    “We often say our job is to stay between the yellow lines,” said Dr. Lawrence Gray, a pediatric developmental specialist at Northwestern University. “When people just decide to go outside of current guidelines, then they’re outside of that. And nobody knows what’s going to happen out there.”

    Related video below: Parents, doctors react to Trump administration claims about Tylenol and autism

    The evidence for leucovorin isn’t settled

    The case for leucovorin’s use in autism begins with established science but quickly veers into uncertain terrain.

    When metabolized, the drug turns into folate, which is essential for healthy prenatal development and is recommended before and during pregnancy. But far less is known about its role after birth.

    The issue caught the attention of Frye and others more than 20 years ago, when research suggested some people with autism had low levels of folate in the brain due to antibodies blocking the vitamin’s absorption.

    The theory linking autism to folate levels was mostly abandoned, however, after research showed that the siblings of people with autism can also have low folates without any symptoms of the condition.

    “I honestly thought this had died out as a theory for autism and was shocked to see its reemergence,” Mandell said.

    In 2018, Frye and his colleagues published a study of 48 children in which those taking leucovorin performed better on several language measures than those taking a placebo.

    Four small studies in other countries, including China and Iran, showed similar results, albeit using different doses, metrics and statistical analyses, which researchers say is problematic.

    Frye struggled to get funding to continue within the traditional academic system.

    “I decided to move out of academia to be more innovative and actually do some of this stuff,” he said.

    Researchers saw an opening to approach Trump’s top health officials

    Earlier this year, Frye and several other researchers formed a new entity, the Autism Discovery Coalition, to pitch their work to Trump administration officials including Health Secretary Robert F. Kennedy Jr.

    “After Kennedy got in, we thought they’d hopefully be friendly to autism scientists,” he said.

    An August meeting with National Institutes of Health Director Jay Bhattacharya quickly led to further discussions with the Food and Drug Administration about testing a proprietary, purified version of leucovorin.

    A new formulation of the decades-old drug would mean new patents, allowing Frye and his yet-to-be-formed drug company to charge far more than the cheap generics currently on the market.

    “We have a lot of investors who are excited about leucovorin and want to do something high quality for kids with autism,” he said.

    But the FDA’s announcement Monday may have scuttled that plan. Instead of previewing a new version, the agency said it would simply update the label on the generic drug to mention use in boosting folate brain levels, including for patients with autism. That’s expected to encourage more doctors to prescribe it and insurers to cover it.

    Promising autism treatments often fail after more study

    Specialists who have spent decades treating autistic patients say it’s important to proceed carefully.

    Gray recalls other experimental treatments that initially looked promising only to fail in larger studies.

    “Small studies often find populations that are very motivated,” Gray said. “But when those therapies are moved into larger studies, the initial positive findings often disappear.”

    Among the challenges facing leucovorin: There isn’t agreement about what portion of autism patients have the folate-blocking antibodies supposedly targeted by the drug.

    Frye screens his patients for the antibodies using a test developed at a laboratory at the State University of New York. Like many specialty tests, it has not been reviewed by the FDA.

    Gray says the only way to definitively test for the antibodies would be by extracting cranial fluid from children with autism through a spinal tap.

    “That’s a big limiting factor in having these large, randomized controlled trials,” Gray said.

    Related video below: Get the Facts on the White House’s claims linking Tylenol and autism

    Online sources are driving interest from parents

    While the Trump administration discusses fast-tracking leucovorin, interest in the drug continues to swirl online, including in forums and social media groups for parents of children with autism.

    Brian Noonan, of Phoenix, found out about the drug earlier this year after asking ChatGPT for the best autism drug options for his 4-year-old son.

    The FDA has never approved any drug for the underlying causes of autism, but the chatbot directed Noonan to Frye’s research.

    After an evaluation and confirmatory blood test, the boy started on a formulation of the drug from a compounding pharmacy in June.

    Within days, Noonan says, he saw improvement in his son’s ability to make eye contact and form sentences.

    “He’s not cured, but these are just areas of improvement,” Noonan said. “It’s been a big thing for us.”

    [ad_2]

    Source link

  • Northwell signs strategic agreement with Enterprise Singapore to advance healthcare | Long Island Business News

    [ad_1]

    has signed a memorandum of understanding with Enterprise Singapore, a government agency that supports the growth of Singaporean companies and their expansion into international markets.

    The agreement creates a formal framework for Singapore-based biomedical firms to engage with Northwell, the largest health system in New York State and among the largest in the U.S. The collaboration is intended to promote innovation in precision medicine, digital health, clinical trials and healthcare operations, with the broader goal of enhancing patient care on a global scale.

    “Northwell is committed to building bridges with international partners that can bring transformative solutions to our patients and communities,” Michael Dowling, president and CEO of Northwell Health, said in a news release about the agreement.

    “Our collaboration with Enterprise Singapore provides an opportunity to connect with some of the most innovative companies in Singapore and accelerate the adoption of new technologies that will shape the future of healthcare,” Dowling said.

    The agreement follows a year of collaboration between Northwell Health’s Global Strategic Partnerships program and Enterprise Singapore as well as Singapore-based companies.

    Enterprise Singapore supports Singapore’s sector by helping companies build capabilities, access funding and form international partnerships.

    “Enterprise Singapore is excited to create new opportunities for collaboration between Singapore biomedical companies and leading health care systems like Northwell Health in the U.S.,” Lee Chuan Teck, chairman of Enterprise Singapore, said in the news release.

    “Together with Northwell Health, we are building pathways to accelerate medical innovations, strengthen US-Singapore partnerships and improve healthcare for people in both countries,” Teck said.


    [ad_2]

    Adina Genn

    Source link

  • Congress targets Chinese influence in health tech. It could come with tradeoffs

    Congress targets Chinese influence in health tech. It could come with tradeoffs

    [ad_1]

    WASHINGTON (AP) — A California biotechnology company that helps doctors detect genetic causes for cancer is among those that could be cut out of the U.S. market over ties to China, underscoring the possible tradeoffs between health innovation and a largely bipartisan push in Congress to counter Beijing’s global influence.

    The competition between the world’s superpowers is hitting Complete Genomics, whose employees, some in white lab coats stitched with U.S. flag arm patches, spin samples in test tubes and huddle around computers in San Jose. Its founder and chief scientific officer said he’s frustrated that geopolitics is interfering with science.

    “It’s just a loss for the research and for the industry,” Radoje Drmanac said.

    The U.S. House this week overwhelmingly passed the BIOSECURE Act, which cites national security in preventing federal money from benefiting Complete Genomics and four other companies linked to China. They work with U.S. drugmakers to develop new medications or help doctors diagnose diseases.

    It is part of a sweeping package of bills aimed at countering China’s influence and power, especially in technology, that Congress largely backed this week. The biotech measure, which cleared the House with a 306-81 vote, now heads to the Senate.

    Supporters say the legislation is necessary to protect Americans’ health care data, reduce reliance on China in the medical supply chain and ensure the U.S. gains an edge in the biotech field, which both countries call crucial to their economy and security.

    Opponents say the bill, which would ban China-linked companies from working with firms that receive U.S. government money, would delay clinical trials and hinder development of new drugs, raise costs for medications and hurt innovation.

    Rep. Brad Wenstrup, an Ohio Republican and the bill’s sponsor, said House approval was the first step in protecting Americans’ genetic data and reversing the trend of relying on Beijing for gene testing and basic medical supplies.

    “For too long, U.S. policy has failed to recognize the twin economic and national security threats posed by China’s domination of particular markets and supply chains,” he said.

    Rep. James Comer, a Kentucky Republican who chairs the House Oversight Committee, said it’s necessary to protect U.S. interests before these companies “become more embedded in the U.S. economy, university systems and federal contracting base.”

    Rep. Jim McGovern, D-Mass., argued that the legislation, which he opposed, should not name specific companies without due process, saying, “If one of these five companies does not belong on the list, too bad, Congress doesn’t like you, and that’s that.”

    Drmanac of Complete Genomics, a subsidiary of China-based company MGI, said the privacy of Americans’ personal information is not a concern because his company’s instruments are only connected to local U.S. servers.

    The company also has argued that Congress should broadly apply data protection standards and requirements rather than targeting a small subset of companies.

    Some analysts see the issue as more about industry competition than protecting people’s personal information from the Chinese government.

    “You want to make sure that American pharmaceutical companies and biotechnology companies are on an even footing in terms of their ability to compete both inside the U.S. market and then also abroad,” said Andrew Reddie, a public policy professor at the University of California, Berkeley, who studies the intersection of technology, politics and security and founded the Berkeley Risk and Security Lab.

    Complete Genomics is listed in the legislation along with BGI, MGI, WuXi AppTec and WuXi Biologics. MGI is a spinoff of BGI, a heavyweight genomics company based in China that offers genetic sequencing services for research purposes in the U.S.

    BGI Group called the bill “a false flag targeting companies under the premise of national security” and said, “We strictly follow rules and laws, and we have no access to Americans’ personal data in any of our work.”

    MGI said the bill would “serve only to stifle competition and foster a monopoly in DNA testing.”

    WuXi AppTec and WuXi Biologics work as contractors providing research, development and manufacturing services for U.S. drugmakers. Such services are considered crucial for American pharmaceutical companies to develop and make new drugs.

    WuXi AppTec said it and others in the industry are concerned about the bill’s impact on biotechnology innovation, drug development, patient care and health care costs. It urged the Senate not to move forward without addressing “these serious consequences.”

    In filings with the U.S. Securities and Exchange Commission, dozens of U.S. biotech companies have flagged the BIOSECURE Act as a concern, saying it could have major effects on the pharmaceutical supply chain because of the industry’s extensive partnerships with Chinese companies.

    Drugmaker Eli Lilly says its third-party suppliers are “sometimes the sole global source for a component” but it has been working to move some development and manufacturing closer to home, which typically takes several years “due to scientific and regulatory complexity and the need to ensure process and product quality.”

    BIO, the largest advocacy group for U.S. biotech companies and research institutions, supports the bill, saying it reinforces the industry’s national security imperative.

    The bill, which gives U.S. companies eight years to break ties with Chinese firms, has provided “a reasonable timeframe” for the decoupling, group CEO John Crowley said.

    ___

    Daley reported from San Jose.

    [ad_2]

    Source link

  • With higher cancer death rates in rural areas, U.Va. seeks to improve prevention, access to clinical trials – WTOP News

    With higher cancer death rates in rural areas, U.Va. seeks to improve prevention, access to clinical trials – WTOP News

    [ad_1]

    For years, doctors, public health experts and researchers have known the risk of dying from cancer is substantially higher if a patient lives in a rural area, compared to an urban area.

    For years, doctors, public health experts and researchers have known the risk of dying from cancer is substantially higher if a patient lives in a rural area, compared to an urban area.

    Now, two University of Virginia Cancer Center experts have outlined steps to improve cancer prevention for millions of rural and medically underserved Americans, and improve their access to cutting-edge clinical trials.

    “Most of the over 50 comprehensive cancer centers are in urban areas,” said Dr. Linda Duska, referring to the National Cancer Institute-Designated Cancer Centers.

    The D.C. region is home to several of those centers.

    In addition to U.Va., Virginia Commonwealth University has achieved the designation, as have the Johns Hopkins University and University of Maryland centers in Baltimore. In D.C., Georgetown Lombardi Comprehensive Cancer Center has earned the designation.

    Patients in rural areas often are unable to reap the benefits of cancer specialists.

    “To see a specialty provider requires a lengthy drive, taking time off work, getting child care, and there are many other socio-economic barriers that limit a patient’s ability to access care,” Duska said.

    “We definitely know that the rural population is at significantly increased risk for multiple health care problems — cancer is just one of them,” she added. “Groups of individuals in rural areas are more likely to have diabetes, they’re more likely to be obese, or more likely to have other conditions that in many ways complicate their lack of access to care.”

    Goal: Bring specialty care to rural areas

    Duska and U.Va. colleague Dr. Kari Ring outlined a plan in the medical journal Gynecologic Oncology they say could ultimately improve cancer care and prevention for more than 75 million people.

    “There are ways to bring our specialty care to the rural areas,” Duska said. “Telehealth can be a great opportunity for rural patients, even if they don’t have access to internet.”

    While in urban areas, telemedicine makes it possible for patients to see and hear their providers in a video chat.

    Duska said in many remote areas, high-speed internet or even cellphone service isn’t an option

    “We can accomplish a lot on a telephone,” in terms of screening high-risk patients. “We can collect family histories, which can be very helpful, and provide education — not just for the patients, but providers, as well.”

    In urban cancer centers, an at-risk patient would be encouraged to have genetic testing.

    “The blood draws can be done locally, once that screening and counseling has been completed on the telephone,” Duska said.

    In addition to screening, Duska and Ring are calling for continued efforts to “decentralize” clinical trials, which typically require participation at urban cancer centers.

    Nationally, in all settings — urban and rural — only 2% to 8% of Americans diagnosed with cancer enroll in a clinical trial, Duska said, meaning they can’t benefit from the latest novel approaches as they’re being developed and tested.

    “There’s a huge explosion right now of treatment opportunities that are targeted to specific mutations in a person’s tumor,” Dusk said. “We’re not just treating a generic tumor, we’re treating your tumor that has a particular mutation.”

    As with screening, Duska and Ring are looking for ways to enable rural patients to have access to clinical trials being run at urban comprehensive cancer centers. Currently, some patients have to pay for travel and lodging to participate in a trial.

    “So patients don’t have to travel to Charlottesville, for example, for a study,” Duska said. “They could get this study at a local hospital, where they feel a lot more comfortable, and that’s much closer to home.”

    Get breaking news and daily headlines delivered to your email inbox by signing up here.

    © 2024 WTOP. All Rights Reserved. This website is not intended for users located within the European Economic Area.

    [ad_2]

    Neal Augenstein

    Source link

  • Older Americans Are About to Lose a Lot of Weight

    Older Americans Are About to Lose a Lot of Weight

    [ad_1]

    Imagine an older man goes in to see his doctor. He’s 72 years old and moderately overweight: 5-foot-10, 190 pounds. His blood tests show high levels of triglycerides. Given his BMI—27.3—the man qualifies for taking semaglutide or tirzepatide, two of the wildly popular injectable drugs for diabetes and obesity that have produced dramatic weight loss in clinical trials. So he asks for a prescription, because his 50th college reunion is approaching and he’d like to get back to his freshman-year weight.

    He certainly could use these drugs to lose weight, says Thomas Wadden, a clinical psychologist and obesity researcher at the University of Pennsylvania, who recently laid out this hypothetical in an academic paper. But should he? And what about the tens of millions of Americans 65 and older who aren’t simply trying to slim down for a cocktail party, but live with diagnosable obesity? Should they be on Wegovy or Zepbound?

    Already, seniors make up 26.6 percent of the people who have been prescribed these and other GLP-1 agonists, including Ozempic, since 2018, according to a report from Truveta, which draws data from a large network of health-care systems. In the coming years, that proportion could rise even higher: The bipartisan Treat and Reduce Obesity Act, introduced in Congress last July, would allow Medicare to cover drug treatments for obesity among its roughly 50 million Part D enrollees above the age of 65; in principle, about two-fifths of that number would qualify as patients. Even if this law doesn’t pass (and it’s been introduced half a dozen times since 2012), America’s retirees will continue to be prescribed these drugs for diabetes in enormous numbers, and they’ll be losing weight on them as well. One way or another, the Boomers will be giving shape to our Ozempic Age.

    Economists say the cost to Medicare of giving new drugs for obesity to just a fraction of this aging generation would be staggering—$13.6 billion a year, according to an estimate published in The New England Journal of Medicine last March. But the health effects of such a program might also be unsettling. Until recently, the very notion of prescribing any form of weight loss whatsoever to an elderly patient—i.e., someone 65 or older—was considered suspect, even dangerous. “Advising weight loss in obese older adults is still shunned in the medical community,” the geriatric endocrinologist Dennis Villareal and his co-authors wrote in a 2013 “review of the controversy” for a medical journal. More than a decade later, clinicians are still struggling to reach consensus on safety, Villareal told me.

    Ample research shows that interventions for seniors with obesity can resolve associated complications. Wadden helped run a years-long, randomized trial of dramatic calorie reduction—using liquid meal replacements, in part—and stringent exercise advice for thousands of overweight adults with type 2 diabetes. “Clearly the people who were older did have benefits in terms of improved glycemic control and blood-pressure control,” he told me. Other, smaller studies led by Villareal find that older people who succeed at losing weight through diet and exercise end up feeling more robust.

    Such outcomes are significant on their own terms, says John Batsis, who treats and studies geriatric obesity at the UNC School of Medicine. “When we talk about older adults, we really need to be thinking about what’s important to older adults,” he told me. “It’s for them to be able to get on the floor and play with their grandchildren, or to be able to walk down the hallway without being completely exhausted.” But weight loss can also have adverse effects. When a person addresses their obesity through dieting alone, as much as 25 percent of the weight they lose derives from loss of muscle, bone, and other fat-free tissue. For seniors who, through natural aging, are already near the threshold of developing a functional impairment, a sudden drop like this could be enfeebling. Wadden’s trial found that, among the people who were on the weight-loss program for more than a decade, their risk of fracture to the hip, shoulder, upper arm, or pelvis increased by 39 percent. An analogous increase has turned up in studies of patients who undergo bariatric surgery, Batsis told me.

    The effect of dieting on muscle and bone can be attenuated, but not prevented, through resistance training. And obesity itself—which is associated with higher bone density, but perhaps also reduced bone quality—may pose its own fracture risks, Batsis said. But even when a weight-loss treatment benefits an older patient, what happens when it ends? People tend to regain fat, but they don’t recover bone and muscle, Debra Waters, the director of gerontology research at the University of Otago, in New Zealand, told me. That makes the long-term effects of these interventions for older adults very murky. “What happens when they’re 80? Are they going to have really poor bone quality, and be at higher risk of fracture? We don’t know,” Waters said. “It’s a pretty big gamble to take, in my opinion.”

    Villareal told me that doctors should apply “the general principle of starting slow and going slow” when their older patients are trying to lose weight. But that approach doesn’t necessarily square with the rapid and remarkable weight loss seen in patients who are taking semaglutide or tirzepatide, which may produce a greater proportional loss of muscle and bone. (For semaglutide, it appears to be about 40 percent.)

    Then again, when given to laboratory animals, GLP-1 drugs seem to tamp down inflammation in the brain; and they’re now in clinical trials to see whether they might slow the progression of Alzheimer’s disease and dementia. Their multiple established benefits could also help seniors address several chronic problems—diabetes, obesity, fatty liver disease, and kidney disease, for instance—all at once. “Such a ‘one-stop shop’ approach can lead to reduction of medication burden, adverse drug events, hypoglycemic episodes, medication costs, and treatment nonadherence,” one team of geriatricians proposed in 2019.

    Overall, Batsis remains optimistic. “As a clinician, I’m very excited about these medications,” he told me. As a scientist, though, he’s inclined to wait and see. It’s surely true that some degree of weight loss is a great idea for some older patients. “But the million-dollar question is: What’s the sweet spot? How much weight is really enough? Is it 5 to 10 percent? Or is it 25 percent? We don’t know.” Waters said that if Medicare is going to pay for people’s Wegovy, then it should also cover scans of their body composition, to help predict how weight loss might affect their muscles and bones. Wadden said he thinks that treatments should be limited to people who have specific, weight-related complications. For everyone else—as for the hypothetical 72-year-old man who is prepping for his college reunion—he counsels prudence.

    To some extent, such advice is beside the point. Older people are already on Ozempic, and they’re already on Trulicity, and some of them are already taking GLP-1 drugs as a treatment for obesity. Truveta reported that the patients in its member health-care systems who are over 65 have received 281,000 prescriptions for GLP-1 drugs across the past five years. Given the network’s size, one can assume that at least 1 million seniors, overall, have already tried these medications. Millions more will try them in the years to come. If we still have questions about their use, mass experience will start providing answers.

    [ad_2]

    Daniel Engber

    Source link

  • Flu Shots Need to Stop Fighting ‘Something That Doesn’t Exist’

    Flu Shots Need to Stop Fighting ‘Something That Doesn’t Exist’

    [ad_1]

    Listen to this article

    Produced by ElevenLabs and NOA, News Over Audio, using AI narration.

    In Arnold Monto’s ideal vision of this fall, the United States’ flu vaccines would be slated for some serious change—booting a major ingredient that they’ve consistently included since 2013. The component isn’t dangerous. And it made sense to use before. But to include it again now, Monto, an epidemiologist and a flu expert at the University of Michigan, told me, would mean vaccinating people “against something that doesn’t exist.”

    That probably nonexistent something is Yamagata, a lineage of influenza B viruses that hasn’t been spotted by global surveyors since March of 2020, shortly after COVID mitigations plummeted flu transmission to record lows. “And it isn’t for lack of looking,” Kanta Subbarao, the director of the WHO’s Collaborating Centre for Reference and Research on Influenza, told me. In a last-ditch attempt to find the missing pathogen, a worldwide network of monitoring centers tested nearly 16,000 influenza B virus samples collected from February to August of last year. Not a single one of them came up Yamagata. “The consensus is that it’s gone,” Cheryl Cohen, the head of South Africa’s Centre for Respiratory Diseases and Meningitis, told me. Officially removing an ingredient from flu vaccines will codify that sentiment, effectively publishing Yamagata’s obituary.

    Last year around this time, Subbarao told me, the WHO was already gently suggesting that the world might want to drop Yamagata from vaccines; by September, the agency had grown insistent, describing the ingredient as “no longer warranted” and urging that “every effort should be made to exclude it as soon as possible.” The following month, an advisory committee to the FDA unanimously voted to speedily adopt that same change.

    But the switch from a four-flu vaccine to a trivalent one, guarding against only three, isn’t as simple as ordering the usual, please, just hold the Yams. Trivalent vaccines require their own licensure, which some manufacturers may have allowed to lapse—or never had at all; manufacturers must also adhere to the regulatory pipelines specific to each country. “People think, ‘They change the strains every season; this should be no big deal,’” Paula Barbosa, the associate director of vaccine policy at the International Federation of Pharmaceutical Manufacturers and Associations, which represents vaccine manufacturers, told me. This situation is not so simple: “They need to change their whole manufacturing process.” At the FDA advisory-committee meeting in October, an industry representative cautioned that companies might need until the 2025–26 season to fully transition to trivalents in the Northern Hemisphere, a timeline that Barbosa, too, considers realistic. The South could take until 2026.

    In the U.S., though, where experts such as Monto have been pushing for expedient change, a Yamagata-less flu vaccine could be coming this fall. When I reached out to CSL Seqirus and GSK, two of the world’s major flu-vaccine producers, a spokesperson from each company told me that their firm was on track to deliver trivalent vaccines to the U.S. in time for the 2024–25 flu season, should the relevant agencies recommend and request it. (The WHO’s annual meeting to recommend the composition of the Northern Hemisphere’s flu vaccine isn’t scheduled until the end of February; an FDA advisory meeting on the same topic will follow shortly after.) Sanofi, another vaccine producer, was less definitive, but told me that, with sufficient notice from health authorities, its plans would allow for trivalent vaccines this year, “if there is a definitive switch.” AstraZeneca, which makes the FluMist nasal-spray vaccine, told me that it was “engaging with the appropriate regulatory bodies” to coordinate the shift to a trivalent vaccine “as soon as possible.”

    Quadrivalent flu vaccines are relatively new. Just over a decade ago, the world relied on immunizations that included two flu A strains (H1N1 and H3N2), plus one B: either Victoria or Yamagata, whichever scientists predicted might be the bigger scourge in the coming flu season. “Sometimes the world got it wrong,” Mark Jit, an epidemiologist at the London School of Hygiene & Tropical Medicine, told me. To hedge their bets, experts eventually began to recommend simply sticking in both. But quadrivalent vaccines typically cost more to manufacture, experts told me. And although several countries, including the U.S., quickly transitioned to the heftier shots, many nations—especially those with fewer resources—never did.

    Now “the extra component is a waste,” Vijay Dhanasekaran, a virologist at the University of Hong Kong, told me. It’s pointless to ask people’s bodies to mount a defense against an enemy that will never attack. Trimming Yamagata out of flu-vaccine recipes should also make them cheaper, Dhanasekaran said, which could improve global access. Plus, continuing to manufacture Yamagata-focused vaccines raises the small but serious risk that the lineage could be inadvertently reintroduced to the world, Subbarao told me, as companies grow gobs of the virus for their production pipeline. (Some vaccines, such as FluMist, also immunize people with live-but-weakened versions of flu viruses.)

    Some of the researchers I spoke with for this article weren’t ready to rule out the possibility—however slim—that Yamagata is still biding its time somewhere. (Victoria, a close cousin of Yamagata, and the other B lineage that pesters people, once went mostly quiet for about a decade, before roaring back in the early aughts.) But most experts, at this point, are quite convinced. The past couple of flu seasons have been heavy enough to offer even a rather rare lineage the chance to reappear. “If it had been circulating in any community, I’m pretty sure that global influenza surveillance would have detected it by now,” Dhanasekaran said. Plus, even before the pandemic began, Yamagata had been the wimpiest of the flu bunch, Jit told me: slow to evolve, crummy at transmitting, and already dipping in prevalence. When responses to the pandemic starved all flu viruses of hosts, he said, this lineage was the likeliest to be lost.

    Eventually, companies may return to including four types of flu in their products, swapping in, say, another strain of H3N2, the most severe and fastest-evolving of the bunch—a change that Subbarao and Monto both told me might actually be preferable. But incorporating a second H3N2 is even more of a headache than returning to a trivalent vaccine: Researchers would likely first need to run clinical trials, experts told me, to ensure that the new components played nicely with each other and conferred additional benefits.

    For the moment, a slimmed-down vaccine is the quickest way to keep up with the flu’s current antics. And in doing so, those vaccines will also reflect the strange reality of this new, COVID-modified world. “A whole lineage of flu has probably been eliminated through changes in human behavior,” Jit told me. Humanity may not have intended it. But our actions against one virus may have forever altered the course of another.

    [ad_2]

    Katherine J. Wu

    Source link

  • Speech Accessibility Project begins recruiting people who have had a stroke

    Speech Accessibility Project begins recruiting people who have had a stroke

    [ad_1]

    BYLINE: Meg Dickinson

    Newswise — The Speech Accessibility Project has begun recruiting U.S. and Puerto Rican adults who have had a stroke.

    Those interested can sign up online.

    Funded by Big Tech companies Amazon, Apple, Google, Meta, and Microsoft, the University of Illinois Urbana-Champaign aims to train voice recognition technologies to understand people with diverse speech patterns and disabilities. The project is also recruiting adults with Parkinson’s diseaseDown syndromecerebral palsy, and amyotrophic lateral sclerosis.

    “A stroke can cause big changes, including changes to your ability to speak,” said Mark Hasegawa-Johnson, the project’s leader and a professor of electrical and computer engineering at Illinois. “Our goal is to teach AI to understand you the way you speak right now, so that you can use AI to help you on the job or in activities of daily life. The Speech Accessibility Project is about empowerment; the potential for empowerment of people post-stroke is huge and wonderful.”

    The project has partnered with Lingraphica’s research team to recruit people who have had a stroke. Mentors will connect with those who want to participate, screen their speech, and help them understand and consent to participate.

    Shawnise Carter, Lingraphica’s senior research manager and a speech language pathologist, said she’s thrilled to join the project and called it “ambitious and necessary.”

    “It is essential for individuals with communication impairments to have access to technology in a way that can suit their needs,” Carter said. “The hope is that it will allow people who have had a stroke to access smart devices and smart technology while decreasing frustration resulting from voice recognition technology not recognizing impaired speech.”

    Such technology doesn’t currently account for people with speech impairments, she said.

    “Creating a database that considers this is a huge contribution to the field of communication sciences and disorders and more research of this nature should continue,” she said.

    Clarion Mendes, a clinical assistant professor of speech and hearing science at Illinois and a speech language pathologist, added that the Speech Accessibility Project could also improve quality of life for family members and loved ones of people who have had a stroke.

    “Communication difficulties associated with a cerebrovascular accident, commonly known as stroke, are diverse in both their severity and how they impact individuals and their families. Speech, language, and cognitive processes may be affected,” Mendes said. “Including stroke survivors with aphasia and their caregivers in the Speech Accessibility Project is an exciting new chapter. There’s outstanding potential for increasing quality of life for stroke survivors and decreasing caregiver burden.”



    [ad_2]

    Beckman Institute for Advanced Science and Technology, University of Illinois at Urbana-Champaign

    Source link

  • Subcutaneous Nivolumab as Effective as IV for Renal Cell Carcinoma — With Much Faster Treatment Time

    Subcutaneous Nivolumab as Effective as IV for Renal Cell Carcinoma — With Much Faster Treatment Time

    [ad_1]

    • Subcutaneous formula slashes treatment time to under 5 minutes
    • Broad impact seen for greater access to and experience with treatment
    • Study has implications for treatment of many cancer types

    Newswise — SAN FRANCISCO — Subcutaneous injection of the immunotherapy nivolumab (brand name Opdivo) is noninferior to intravenous delivery and dramatically reduces treatment time in patients with renal cell carcinoma, as seen in the results of a large phase 3 clinical trial reported today at the 2024 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium in San Francisco, California. Saby George, MD, FACP, Professor of Oncology and Medicine and Director of Network Clinical Trials at Roswell Park Comprehensive Cancer Center, will deliver an oral abstract summarizing the findings of “A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants with Previously Treated Clear Cell Renal Carcinoma That Is Advanced or Has Spread (CheckMate-67T)” (NCT04810078).

     “The burden of treatment felt by cancer patients is tremendous. If nivolumab can be given as a subcutaneous injection instead of an intravenous infusion, their treatment experience will be significantly improved,” says Dr. George, who is the presenting author, a member of the clinical trial steering committee and site principal investigator at Roswell Park. “Instead of one hour in an infusion chair, they will get the injection done in five minutes.”

    He points to the high demand for infusion chair appointments at most cancer centers, which can result in treatment delays of a week or more.

    “If nivolumab becomes available subcutaneously, we can administer it in the clinic instead of sending patients to infusion centers,” he says. That outcome could simultaneously speed treatment time for patients receiving nivolumab and shorten wait times for patients who still need to receive treatment in an infusion center.

    The availability of injectable nivolumab could also reduce health disparities. “One of the major problems is access to treatment,” says Dr. George, noting that some patients live a long distance from an infusion center and do not have a way to get there. “Patients who don’t live near an infusion center could get treatment closer to home, at a clinic, and that could improve access and help reduce disparities.”

    Sponsored by Bristol Myers Squibb, the drug’s manufacturer, the clinical trial began in May 2021, randomizing 495 patients at 73 centers in 17 countries. Roswell Park was one of only three participating sites in the U.S. and the only one in New York State.

    Patients in the study had advanced or metastatic renal cell carcinoma, had received no more than two prior treatments with systemic therapies and no prior immunotherapy. They were randomized 1:1 to receive nivolumab either subcutaneously or intravenously. Nivolumab is FDA-approved and the standard-of-care treatment for those patients.

    The study’s primary objective was to evaluate the pharmacokinetics of subcutaneous vs. intravenous delivery — how the body interacted with the nivolumab, including whether blood levels of the drug were comparable in the two groups over time. Those measures included the daily average concentration of the drug in the blood over 28 days (Cavgd28) and the concentration of the drug at the end of the dosing cycle (Cminss). Both measures were noninferior to intravenous nivolumab, as evidenced in pharmacokinetic measures and overall response rate.

    The objective response rate for the subcutaneous group — the percentage of patients who achieved a complete or partial response, measured by blinded independent central review — proved noninferior to the intravenous group, at 24.2% vs. 18.2%, respectively. Median progression-free survival stood at 7.23 months for the subcutaneous group vs. 5.65 months for the IV group. The safety profile was similar for both groups.

    More than 80,000 new cases of renal cell carcinoma are diagnosed in the U.S. each year.

    Because nivolumab is already FDA-approved for more than 20 indications across multiple malignancies, CheckMate-67T will likely serve as a gateway to additional studies evaluating the effectiveness of the subcutaneous formula in other patient populations.

    “This is a groundbreaking achievement for patients and physicians, and will definitely make treatment easier for patients,” says Dr. George.

    ASCO GU Presentation Details

    Abstract LBA360: “Subcutaneous nivolumab (NIVO SC) vs. intravenous nivolumab (NIVO IV) in patients with previously treated advanced or metastatic clear cell renal cell carcinoma (ccRCC): Pharmacokinetics (PK), efficacy, and safety results from CheckMate 67T.”

    Time/date: Saturday, Jan. 27, 2024, 8:47 a.m. PST, Moscone West, Level 3, Ballroom

    ###

    From the world’s first chemotherapy research to the PSA prostate cancer biomarker, Roswell Park Comprehensive Cancer Center generates innovations that shape how cancer is detected, treated and prevented worldwide. Driven to eliminate cancer’s grip on humanity, the Roswell Park team of 4,000 makes compassionate, patient-centered cancer care and services accessible across New York State and beyond. Founded in 1898, Roswell Park was among the first three cancer centers nationwide to become a National Cancer Institute-designated comprehensive cancer center and is the only one to hold this designation in Upstate New York. To learn more about Roswell Park Comprehensive Cancer Center and the Roswell Park Care Network, visit www.roswellpark.org, call 1-800-ROSWELL (1-800-767-9355) or email [email protected].



    [ad_2]

    Roswell Park Comprehensive Cancer Center

    Source link

  • ‘If Exercise Could Cure This, I Would Have Been Cured So Quickly’

    ‘If Exercise Could Cure This, I Would Have Been Cured So Quickly’

    [ad_1]

    In the weeks after she caught COVID, in May 2022, Lauren Shoemaker couldn’t wait to return to her usual routine of skiing, backpacking, and pregaming her family’s eight-mile hikes with three-mile jogs. All went fine in the first few weeks after her infection. Then, in July, hours after finishing a hike, Shoemaker started to feel off; two days later, she couldn’t make it to the refrigerator without feeling utterly exhausted. Sure it was a fluke, she tried to hike again—and this time, was out of commission for months. Shoemaker, an ecologist at the University of Wyoming, couldn’t do her alpine fieldwork; she struggled to follow a movie with a complex plot. She was baffled. Exercise, the very thing that had reliably energized her before, had suddenly become a trigger for decline.

    For the majority of people, exercise is scientifically, physiologically, psychologically good. It boosts immunity, heart function, cognition, mood, energy, even life span. Doctors routinely prescribe it to patients recovering from chronic obstructive pulmonary disease and heart attacks, managing metabolic disease, or hoping to stave off cognitive decline. Conditions that worsen when people strive for fitness are very rare. Post-exertional malaise (PEM), which affects Shoemaker and most other people with long COVID, just happens to be one of them.

    PEM, first described decades ago as a hallmark of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), is now understood to fundamentally alter the body’s ability to generate and use energy. For people with PEM, just about any form of physical, mental, or emotional exertion—in some cases, activities no more intense than answering emails, folding laundry, or digesting a particularly rare steak—can spark a debilitating wave of symptoms called a crash that may take weeks or months to abate. Simply sitting upright for too long can leave Letícia Soares, a long-hauler living in Brazil, temporarily bedbound. When she recently moved into a new home, she told me, she didn’t bother buying a dining table or chairs—“it just felt useless.”

    When it comes to PEM, intense exercise—designed to boost fitness—is “absolutely contraindicated,” David Putrino, a physical therapist who runs a long-COVID clinic at Mount Sinai, in New York, told me. And yet, the idea that exertion could undo a person rather than returning them to health is so counterintuitive that some clinicians and researchers still endorse its potential benefits for those with PEM; it’s dogma that Shoemaker heard repeatedly after she first fell ill. “If exercise could cure this,” she told me, “I would have been cured so quickly.”

    The problem is, there’s no consensus about what people who have PEM should do instead. Backing off physical activity too much might start its own downward spiral, as people lose muscle mass and strength in a phenomenon called deconditioning. Navigating the middle ground between deconditioning and crashing is “where the struggle begins,” Denyse Lutchmansingh, a pulmonary specialist at Yale, told me. And as health experts debate which side to err on, millions of long-haulers are trying to strike their own balance.


    Though it’s now widely accepted that PEM rejiggers the body’s capacity for strain, scientists still aren’t sure of the precise biological causes. Some studies have found evidence of impaired blood flow, stymieing the delivery of oxygen to cells; others have discovered broken mitochondria struggling to process raw fuel into power. A few have seen hints of excessive inflammation, and immune cells aberrantly attacking muscles; others point to issues with recovery, perhaps via a slowdown in the clearance of lactate and other metabolic debris.

    The nature of the crashes that follow exertion can be varied, sprawling, and strange. They might appear hours or days after a catalyst. They can involve flu-like coughs or sore throats. They may crater a patient’s cognitive capacity or plague them with insomnia for weeks; they can leave people feeling so fatigued and pained, they’re almost unable to move. Some of Shoemaker’s toughest crashes have saddled her with tinnitus, numbness, and extreme sensitivity to sound and light. Triggers can also change over time; so can people’s symptoms—even the length of the delay before a crash.

    But perhaps the worst part is what an accumulation of crashes can do. Rob Wüst, who studies skeletal-muscle physiology at Amsterdam University Medical Center, told me that his team has found an unusual amount of muscle damage after exertion in people with PEM that may take months to heal. People who keep pushing themselves past their limit could watch their baseline for exertion drop, and then drop again. “Every time you PEM yourself, you travel a little further down the rabbit hole,” Betsy Keller, an exercise physiologist at Ithaca College, told me.

    Still, the goal of managing PEM has never been to “just lay in a bed all day and don’t do anything,” Lily Chu, the vice president of the International Association for Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (IACFS/ME), told me. In the 1960s, a group of scientists found that three weeks of bed rest slashed healthy young men’s capacity for exertion by nearly 30 percent. (The participants eventually trained themselves back to baseline.) Long periods of bed rest were once commonly prescribed for recovery from heart attacks, says Prashant Rao, a sports cardiologist at Beth Israel Deaconess Medical Center, in Massachusetts. But now too much rest is actively avoided, because “there’s a real risk of spiraling down, and symptoms worsening,” Rao told me. “I really fear for that, even for people with PEM.”

    There is no rulebook for threading this needle, which has led researchers to approach treatments and rehabilitation for long COVID in different ways. Some clinical trials that involve exercise as an intervention explicitly exclude people with PEM. “We did not feel like the exercise program we designed would be safe for those individuals,” Johanna Sick, a physiologist at the University of Vienna who is helping run one such trial, told me.

    Other researchers hold out hope that activity-based interventions may still help long-haulers, and are keeping patients with PEM in experiments. But some of those decisions have been controversial. The government-sponsored RECOVER trial was heavily criticized last year for its plan to enroll long-haulers in an exercise study. Scientists have since revised the trial’s design to reroute participants with moderate to severe PEM to another intervention, according to Adrian Hernandez, the Duke cardiologist leading the trial. The details are still being finalized, but the plan is to instead look at pacing, a strategy for monitoring activity levels to ensure that people stay below their crash threshold, Janna Friedly, a physiatrist at the University of Washington who’s involved in the trial, told me.

    Certain experimental regimens can be light enough—stretching, recumbent exercises—to be tolerable by many (though not all) people with PEM. Some researchers are trying to monitor participants’ heart rate, and having them perform only activities that keep them in a low-intensity zone. But even when patients’ limitations are taken into account, crashes can be hard to avoid, Tania Janaudis-Ferreira, a physiotherapist at McGill University, in Quebec, told me. She recently wrapped a clinical trial in which, despite tailoring the regimen to each individual, her team still documented several mild to moderate crashes among participants with PEM.

    Just how worrisome crashes are is another matter of contention. Pavlos Bobos, a musculoskeletal-health researcher at the University of Western Ontario, told me that he’d like to see more evidence of harm before ruling out exercise for long COVID and PEM. Bruno Gualano, a physiologist at the University of São Paulo, told me that even though crashes seem temporarily damaging, he’s not convinced that exercise worsens PEM in the long term. But Putrino, of Mount Sinai, is adamant that crashes set people back; most other experts I spoke with agreed. And several researchers told me that, because PEM seems to upend basic physiology, reduced activity may not be as worrisome for people with the condition as it is for those without.

    For Shoemaker, the calculus is clear. “Coming back from being deconditioned is honestly trivial compared to recovering from PEM,” she told me. She’s willing to wait for evidence-based therapies that can safely improve her PEM. “Whatever we figure out, if I could get healthy,” she told me, “then I can get back in shape.”


    At this point, several patients and researchers told me, most exercise-based trials for long COVID seem to be at best a waste of resources, and at worst a recipe for further harm. PEM is not new, nor are the interventions being tested. Decades of research on ME/CFS have already shown that traditional exercise therapy harms more often than it helps. (Some researchers insisted that more PEM studies are needed in long-haulers—just in case the condition diverges substantially from its manifestation in ME/CFS.) And although a subset of long-haulers could be helped by exercise, experts don’t yet have a great way to safely distinguish them from the rest.

    Even pacing, although often recommended for symptom management, is not generally considered to be a reliable treatment, which is where most long-COVID patient advocates say funds should be focused. Ideally, Putrino and others told me, resources should be diverted to trials investigating drugs that might address PEM’s roots, such as the antiviral Paxlovid, which could clear lingering virus from long-haulers’ tissues. Some researchers are also hopeful about pyridostigmine, a medication that might enhance the delivery of oxygen to tissues, as well as certain supplements that might support mitochondria on the fritz.

    Those interventions are still experimental—and Putrino said that no single one is likely to work for everyone. That only adds to the challenge of studying PEM, which has been shrouded in disbelief for decades. Despite years of research on ME/CFS, Chu, of the IACFS/ME, told me that many people with the condition have encountered medical professionals who suggest that they’re just anxious, even lazy. It doesn’t help that there’s not yet a blood test for PEM; to diagnose it, doctors must ask their patients questions and trust the answers. Just two decades ago, researchers and physicians speculated that PEM stemmed from an irrational fear of activity; some routinely prescribed therapy, antidepressants, and just pushing through, Chu said. One highly publicized 2011 study, since widely criticized as shoddy science, appeared to support those claims—influencing treatment recommendations from top health authorities such as the CDC.

    The CDC and other organizations have since reversed their position on exercise and cognitive behavioral therapy as PEM treatments. Even so, many people with long COVID and ME/CFS are still routinely told to blow past their limits. All of the long-haulers I spoke with have encountered this advice, and learned to ignore it. Fighting those calls to exercise can be exhausting in its own right. As Ed Yong wrote in The Atlantic last year, American society has long stigmatized people who don’t push their way through adversity—even if that adversity is a medically documented condition that cannot be pushed through. Reconceptualizing the role of exercise in daily living is already a challenge; it is made all the more difficult when being productive—even overworked—is prized above all else.

    Long-haulers know that tension intimately; some have had to battle it within themselves. When Julia Moore Vogel, a researcher at Scripps, developed long COVID in the summer of 2020, she was at first determined to grit her way through. She took up pilates and strength training, workouts she at the time considered gentle. But the results were always the same: horrific migraines that relegated her to bed. She now does physical therapy to keep herself moving in safe and supervised amounts. When Vogel, a former competitive runner, started her program, she was taken aback by how little she was asked to do—sometimes just two reps of chin tucks. “I would always laugh because I would be like, ‘These are not exercises,’” she told me. “I’ve had to change my whole mental model about what exercise is, what exertion is.”

    [ad_2]

    Katherine J. Wu

    Source link

  • The Ozempic Plateau

    The Ozempic Plateau

    [ad_1]

    The latest weight-loss drugs are rightly hailed as game changers for obesity, but in an important way, they are just like every other method of managing weight: They work only to a point for weight loss. The pounds melt off quickly at first and then gradually and then not at all. You can’t lose any more no matter what you do. You’ve hit the weight-loss plateau.

    It happens with dieting. It happens with bariatric surgery. And it happens now with both semaglutide (better known as Ozempic or Wegovy, depending on whether it’s prescribed for diabetes or weight loss) and tirzepatide (better known as Mounjaro or Zepbound). Weight loss triggers a set of powerful physiological changes in the body, which evolved over millions of years to keep us alive through periods of food scarcity. “Everybody plateaus,” says Jamy Ard, an obesity doctor at Wake Forest University. Exactly when varies quite a bit from person to person, but it happens after losing a certain percentage of body weight—meaning some people might plateau while still meeting the criteria for obesity.

    For Wegovy, it’s after losing, on average, 15 percent, usually more than a year into starting the drug. For Zepbound, it’s about 20 percent. These numbers are higher than is sustainable through diet and exercise alone, but they also do not reach the 30 percent achievable via the gold standard of bariatric surgery.

    These differences matter because they suggest that the level of the plateau is not permanently fixed. Recent advances in understanding the gut hormones that these drugs are designed to mimic hint at a possibility of even more powerful weight-loss drugs. Scientists are now testing ways to push the plateau down further; a drug could one day be even more effective than bariatric surgery.

    All of this raises an unsettled question: “How much weight loss is enough?” says Jonathan Campbell, who studies gut hormones at Duke. In studies, even 5 to 15 percent weight loss can substantially reverse high blood pressure, high blood sugar, and high cholesterol. Yet a patient who starts at 375 pounds with a BMI of 60 might still find themselves ineligible for a joint replacement that requires a BMI below 40, flawed as BMI may be. Or they may simply want to look thinner. The explosion of weight-loss drugs has reopened thorny questions about how they should be used, but nevertheless, pharmaceutical companies are racing ahead to develop more and more powerful ones.


    Weight loss is easiest at the beginning, before your body starts actively working against it. “Your brain doesn’t know you’re trying to lose weight on purpose,” Ard says. And once it notices, “it thinks that something is wrong.” So your body tries very, very hard to compensate.

    First of all, you become hungrier, obviously. And not just because you want to eat as much as you did before; you actually want to eat more than you did prior to losing weight. “With every one kilogram you lose, your appetite goes up above baseline by 90 or so calories per day,” says Kevin Hall, who studies metabolism at the National Institute of Diabetes and Digestive and Kidney Diseases. At the same time, your body looks for ways to conserve energy. Your muscles work more efficiently, for example, Ard says, so walking that normally burned 100 calories might now burn only 90. By making you want to eat more and burning fewer calories, your body is eventually able to slow weight loss down to zero. Here is your plateau. This is, all told, a remarkably elegant and robust system, if what you wanted to do is to maintain your weight.

    If you’re in fact trying to lose more weight, the plateau is psychologically frustrating. The same diet, the same exercise routine, the drug on which you were just losing weight will seem to have stopped working—but they haven’t. (If they did actually stop working, you would be regaining weight.) But your body is now fighting so hard against the weight loss that it requires a persistent effort just to keep the weight off, Hall says. Should you ease up, the weight will come right back, as seen in yo-yo dieting or weight regain after stopping Wegovy or Zepbound.

    The only way to get past a plateau is to up the intensity or number of interventions. Doctors might recommend, for example, bariatric surgery and a weight-loss drug. But in the future, novel drugs might be able to pharmacologically up the intensity. The progression from Wegovy to the more effective Zepbound has in fact already brought us one step closer.


    Wegovy and Zepbound both belong to a class of drugs that mimic a gut hormone called GLP-1. Both of these drugs bind GLP-1 receptors in the brain, which seems to reduce hunger. Zepbound goes a step further, though. It can also bind receptors for a second gut hormone, called GIP. Years ago, researchers noticed that bariatric surgery changes the balance of gut hormones in the body, including GLP-1 and GIP. This—and not just the physical shrinking of the stomach—is now understood to be a key driver of weight loss, to the point that bariatric surgery is sometimes called “metabolic surgery.” These observations inspired research into drugs that target not just GLP-1 but also GIP and other hormones. Essentially, they’re performing metabolic surgery with a drug rather than a scalpel.

    Exactly why Zepbound outperforms Wegovy is still unclear. One obvious hypothesis is that it mimics a second gut hormone; the more hormonal pathways it can influence, perhaps, the more body parts it affects and the more weight loss it triggers. And a recent clinical trial of retatrutide, a further modified derivative of Zepbound that mimics a third hormone called glucagon, demonstrated even greater weight loss: 24 percent at the highest dose.

    A second hypothesis suggests that the difference between Wegovy and Zepbound still goes back to GLP-1. Although both drugs bind that receptor, they tickle it slightly differently, setting off slightly different chain reactions. Wegovy seems to also activate some cellular machinery that acts as a break, possibly limiting its efficacy. This suggests another strategy for fine-tuning gut-hormone drugs: Companies have so far focused on trying to design one drug that binds to multiple hormone receptors, like a master key that can open three different locks. This was a practical choice, Campbell says, because trying to study three separate new drugs in clinical trials would be a logistical “nightmare.” But the optimal combination for weight loss might actually require individual keys that can jigger individual receptors in just the right way—that is, a double or triple combination of drugs.

    It may also eventually be possible to keep increasing the dosage of GLP-1 drugs to push the weight-loss plateau down. Right now, the dose is limited by what people are willing to tolerate. The drugs can cause severe nausea, vomiting, and diarrhea, so they have to be ramped up slowly over many weeks to induce tolerance and minimize side effects. But Novo Nordisk is trialing the drug in Wegovy at up to 16 milligrams a week, more than six times the current maximum dose. Tinkering with other gut-hormone pathways could also help with side effects. GIP receptors, for example, are found in neurons whose activation might suppress nausea, which may in part be why Zepbound seems to have slightly milder side effects.

    Zepbound is likely the first of many leveling-ups from single-action GLP-1 drugs. Even as the science advances, no safe method of losing weight is meant to eliminate the weight-loss plateau—and indeed, you wouldn’t want to keep losing weight indefinitely. But lose more weight? Pharmaceutical companies are betting on a market for that. With obesity drugs projected to become a $100 billion industry by 2030, they are eager for a slice of that massive pie. “The dollar signs are so big now,” Campbell says. Zepbound is the newest weight-loss drug on the block, but it too may eventually be old news.

    [ad_2]

    Sarah Zhang

    Source link

  • Some mosquitoes like it hot

    Some mosquitoes like it hot

    [ad_1]

    Newswise — Certain populations of mosquitoes are more heat tolerant and better equipped to survive heat waves than others, according to new research from Washington University in St. Louis.

    This is bad news in a world where vector-borne diseases are an increasingly global health concern. Most models that scientists use to estimate vector-borne disease risk currently assume that mosquito heat tolerances do not vary. As a result, these models may underestimate mosquitoes’ ability to spread diseases in a warming world.

    Researchers led by Katie M. Westby, a senior scientist at Tyson Research Center, Washington University’s environmental field station, conducted a new study that measured the critical thermal maximum (CTmax), an organism’s upper thermal tolerance limit, of eight populations of the globally invasive tiger mosquito, Aedes albopictus. The tiger mosquito is a known vector for many viruses including West Nile, chikungunya and dengue.

    “We found significant differences across populations for both adults and larvae, and these differences were more pronounced for adults,” Westby said. The new study is published Jan. 8 in Frontiers in Ecology and Evolution.

    Westby’s team sampled mosquitoes from eight different populations spanning four climate zones across the eastern United States, including mosquitoes from locations in New Orleans; St. Augustine, Fla.; Huntsville, Ala.; Stillwater, Okla.; St. Louis; Urbana, Ill.; College Park, Md.; and Allegheny County, Pa.

    The scientists collected eggs in the wild and raised larvae from the different geographic locations to adult stages in the lab, tending the mosquito populations separately as they continued to breed and grow. The scientists then used adults and larvae from subsequent generations of these captive-raised mosquitoes in trials to determine CTmax values, ramping up air and water temperatures at a rate of 1 degree Celsius per minute using established research protocols.

    The team then tested the relationship between climatic variables measured near each population source and the CTmax of adults and larvae. The scientists found significant differences among the mosquito populations.

    The differences did not appear to follow a simple latitudinal or temperature-dependent pattern, but there were some important trends. Mosquito populations from locations with higher precipitation had higher CTmax values. Overall, the results reveal that mean and maximum seasonal temperatures, relative humidity and annual precipitation may all be important climatic factors in determining CTmax.

    “Larvae had significantly higher thermal limits than adults, and this likely results from different selection pressures for terrestrial adults and aquatic larvae,” said Benjamin Orlinick, first author of the paper and a former undergraduate research fellow at Tyson Research Center. “It appears that adult Ae. albopictus are experiencing temperatures closer to their CTmax than larvae, possibly explaining why there are more differences among adult populations.”

    “The overall trend is for increased heat tolerance with increasing precipitation,” Westby said. “It could be that wetter climates allow mosquitoes to endure hotter temperatures due to decreases in desiccation, as humidity and temperature are known to interact and influence mosquito survival.”

    Little is known about how different vector populations, like those of this kind of mosquito, are adapted to their local climate, nor the potential for vectors to adapt to a rapidly changing climate. This study is one of the few to consider the upper limits of survivability in high temperatures — akin to heat waves — as opposed to the limits imposed by cold winters.

    “Standing genetic variation in heat tolerance is necessary for organisms to adapt to higher temperatures,” Westby said. “That’s why it was important for us to experimentally determine if this mosquito exhibits variation before we can begin to test how, or if, it will adapt to a warmer world.”

    Future research in the lab aims to determine the upper limits that mosquitoes will seek out hosts for blood meals in the field, where they spend the hottest parts of the day when temperatures get above those thresholds, and if they are already adapting to higher temperatures. “Determining this is key to understanding how climate change will impact disease transmission in the real world,” Westby said. “Mosquitoes in the wild experience fluctuating daily temperatures and humidity that we cannot fully replicate in the lab.”

    [ad_2]

    Washington University in St. Louis

    Source link

  • First-in-human clinical trial of CAR T cell therapy with new binding mechanism shows promising early responses

    First-in-human clinical trial of CAR T cell therapy with new binding mechanism shows promising early responses

    [ad_1]

    Newswise — SAN DIEGO – Early results from a Phase I clinical trial of AT101, a new CAR T cell therapy that uses a distinct binding mechanism to target CD19, show a 100 percent complete response (CR) rate at the higher dose levels studied in the trial, according to researchers from the University of Pennsylvania Perelman School of Medicine and Penn Medicine’s Abramson Cancer Center. The findings were published today in Molecular Cancer and presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition (Abstract 2096).

    CAR T cell therapy has revolutionized treatment for many people with blood cancers who had run out of other treatment options. While some patients experience long-term responses to CAR T cell therapy, it doesn’t work–or the cancer eventually returns–for others. The CD19 CAR T cell therapies that are currently approved all target CD19 through the same epitope (FMC63). To try and make CD19 CAR T cell therapy more effective for more patients, Marco Ruella, MD, an assistant professor of Hematology-Oncology and Scientific Director of the Lymphoma Program, and his research team, along with the Korean company AbClon Inc, co-developed a CAR T product (AT101), using cells originating from the same patient, that targets CD19 through a different epitope, located closer to the cell membrane, via a novel antibody (h1218). In preclinical studies, the team previously demonstrated that h1218-CART19 had decreased T cell exhaustion and improved control compared to FMC63-CART19.

    The Phase I first-in-human clinical trial (NCT05338931) was conducted in South Korea and enrolled 12 patients with relapsed or refractory B cell non-Hodgkin’s lymphoma (NHL). The study was designed to increase the dose level of AT101 after safety was confirmed in the first six patients. After a median follow-up of 6.5 months, all six patients who received dose level 2 or higher experienced a complete response and their cancer has not relapsed.  

    “We’ve learned that the way you design your CAR really matters. Designing a different CAR might drastically change the way the T cells work, potentially allowing that CAR T cell product to work where other CAR T cell products have failed,” Ruella said. “We were not expecting such a drastic early difference in this study. The CART19 products that are already FDA-approved are very effective, and it’s not easy to do better. While there is not a randomized trial of this product yet, the initial results seem very promising, and we look forward to moving into the planned Phase II portion of the study.”

    The drug was found to be safe, with manageable side effects, including cytokine-release syndrome in four patients and immune-cell-related neurotoxicity syndrome in three patients. One patient experienced grade 3 sepsis that resolved; the same patient later developed fatal neutropenic septic shock outside the dose-limiting toxicity time frame.

    The Phase I study enrolled patients who had not previously received any other CAR19 therapy. In the Phase II expansion, the study will also include patients who have previously received CAR19 therapy.

    Editor’s Note: The study was funded by AbClon Inc; Ruella is a paid consultant for the company and has a Sponsored Research Agreement with them.

    Yunlin Zhang, MS, a research specialist in Ruella’s lab, will present the findings in a poster session on Saturday, Dec. 9, from 5:30 to 7:30 p.m. PT in the San Diego Convention Center Halls G-H.

    ###

    Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, excellence in patient care, and community service. The organization consists of the University of Pennsylvania Health System and Penn’s Raymond and Ruth Perelman School of Medicine, founded in 1765 as the nation’s first medical school.

    The Perelman School of Medicine is consistently among the nation’s top recipients of funding from the National Institutes of Health, with $550 million awarded in the 2022 fiscal year. Home to a proud history of “firsts” in medicine, Penn Medicine teams have pioneered discoveries and innovations that have shaped modern medicine, including recent breakthroughs such as CAR T cell therapy for cancer and the mRNA technology used in COVID-19 vaccines.

    The University of Pennsylvania Health System’s patient care facilities stretch from the Susquehanna River in Pennsylvania to the New Jersey shore. These include the Hospital of the University of Pennsylvania, Penn Presbyterian Medical Center, Chester County Hospital, Lancaster General Health, Penn Medicine Princeton Health, and Pennsylvania Hospital—the nation’s first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.

    Penn Medicine is an $11.1 billion enterprise powered by more than 49,000 talented faculty and staff.

    [ad_2]

    Perelman School of Medicine at the University of Pennsylvania

    Source link

  • Pfizer to discontinue twice-daily weight loss pill due to high rates of adverse side effects

    Pfizer to discontinue twice-daily weight loss pill due to high rates of adverse side effects

    [ad_1]

    Pfizer on Friday said it would stop developing the twice-daily version of its experimental weight loss pill after obese patients taking the drug lost significant weight but had trouble tolerating the drug in a mid-stage clinical study

    The drugmaker observed high rates of adverse side effects, which were mostly mild and gastrointestinal, among patients. A significant share of patients also stopped taking the drug.

    “At this time, twice-daily danuglipron formulation will not advance into Phase 3 studies,” the company said.

    But Pfizer said it still plans to release phase two trial data on a once-a-day version of the drug in the first half of 2024, which will “inform a path forward.” The pharmaceutical giant will wait to see that data before deciding whether to start a phase three study on the once-daily pill, which Wall Street views as the more competitive form of the treatment.

    Shares of Pfizer fell 4% in premarket trading Friday after it announced the trial results.

    Still, the data on the twice-daily drug is a blow to Pfizer’s hopes to win a $10 billion slice of the booming weight loss drug market, which CEO Albert Bourla has said could grow to $90 billion. The company is betting on a successful weight loss pill to help it rebound from plummeting demand for its Covid products and a roughly 40% share price drop this year. 

    But investors have been pessimistic about Pfizer’s potential in the weight loss drug space since the company scrapped a different once-daily pill in June and proceeded with the less attractive danuglipron. Now, Friday’s data puts Pfizer even further behind the dominant players in the weight loss drug market, Eli Lilly and Novo Nordisk, which are racing to develop more convenient pill versions of their blockbuster weight loss and diabetes injections. 

    Pfizer’s phase two trial on its twice-daily pill followed around 600 obese adults who did not have Type 2 diabetes. The trial examined the drug’s effect on weight loss after 26 or 32 weeks, at different dosage amounts ranging from 40 milligrams to 200 milligrams.

    Like Novo Nordisk’s Wegovy and Ozempic, Pfizer’s pill works by mimicking a hormone produced in the gut called GLP-1, which signals to the brain when a person is full.

    Pfizer said the trial on danuglipron met the primary goal of demonstrating “statistically significant” reductions in body weight.

    Patients who took the pill twice a day lost 6.9% to 11.7% of their body weight on average at 32 weeks, and from 4.8% to 9.4% at 26 weeks.

    Meanwhile, patients on a placebo gained 1.4% of their body weight at 32 weeks and 0.17% at 26 weeks.

    When adjusting for the difference between the weight gain observed in patients who took the placebo, Pfizer’s twice-daily pill caused 8% to 13% weight loss on average at 32 weeks and 5% to 9.5% at 26 weeks.

    The company said high rates of adverse events were observed among patients in the study, with up to 73% experiencing nausea, up to 47% vomiting and up to 25% experiencing diarrhea. More than 50% of patients across all dose sizes stopped taking the pill, compared to roughly 40% among those on the placebo, according to Pfizer.

    No new safety issues were observed, and danuglipron was not associated with increased liver enzymes like Pfizer’s other discontinued weight loss pill.

    Data from the phase two trial will be presented at a future scientific conference or published in a peer-reviewed journal.

    Wall Street’s expectations

    The tolerability issues align with some analysts’ predictions ahead of the data release. 

    Leerink Partners analyst David Risinger wrote in a Monday note that the proportion of patients who discontinue treatment with Pfizer’s twice-daily danuglipron in the phase two trial would likely be higher than those who stopped taking a once-daily pill from Eli Lilly.

    By comparison, 10% to 21% of patients who took Eli Lilly’s pill, orforglipron, in a mid-stage trial discontinued the treatment at 32 weeks due to adverse side effects, he noted.

    Risinger said that’s likely because danuglipron’s total daily dose is far higher, which may cause more adverse effects. Patients on the highest dose size of Pfizer’s pill took 400 milligrams each day, while those on the highest dosage of Eli Lilly’s drug took 45 milligrams a day.

    Pfizer’s phase-two trial also didn’t allow downtitration, or decreasing the dose of a drug over time once a specific response has been achieved. Eli Lilly’s mid-stage trial on its pill did. 

    There is hope that patients will better tolerate the once-daily version of danuglipron compared to the twice-daily form. Pfizer appears to believe a once-daily version of the drug could lessen gastrointestinal side effects, according to some analysts.

    They pointed to Pfizer’s second-quarter earnings call, when the company’s chief scientific officer, Mikael Dolsten, suggested that a once-daily version may improve a patient’s tolerability of the drug, which could lessen the gastrointestinal side effects “that have been seen as limiting” danuglipron.

    But the effects will be unclear until the mid-stage trial data is released next year.

    Notably, the weight loss caused by twice-daily danuglipron appeared to fall short of analysts’ expectations. 

    Ahead of the data release, several analysts said Pfizer’s twice-daily pill has to be about as effective as Eli Lilly’s once-a-day pill to be competitive. That means at least a 14% to 15% weight loss, Cantor Fitzgerald analyst Louise Chen told CNBC earlier this month.

    Risinger also wrote in October that Pfizer’s danuglipron needs to show weight reduction in the “mid-teens” percentages to be considered competitive with Eli Lilly’s pill. 

    Obese or overweight patients who took 45 milligrams of Eli Lilly’s pill once a day lost up to 14.7% of their body weight, or 34 pounds, after 36 weeks, according to the company’s phase-two trial results.

    Eli Lilly’s results appear consistent with the weight reduction caused by a high-dose oral version of Novo Nordisk’s semaglutide – the active ingredient used in the diabetes drug Ozempic and weight loss treatment Wegovy – but came over a shorter trial period.

    More than 2 in 5 adults have obesity, according to the National Institutes of Health. About 1 in 11 adults have severe obesity.

    Clarification: This story was updated to reflect that some weight-loss data was adjusted to include results from the placebo group.

    [ad_2]

    Source link

  • Traditional Chinese medicine proves effective in modern clinical trial

    Traditional Chinese medicine proves effective in modern clinical trial

    [ad_1]

    A traditional Chinese medicine has been shown to be effective at reducing complications following a heart attack after a large-scale, clinical trial.

    The medicine, known as tongxinluo, is made of extracts derived from seven herbs and various animals—including cockroaches, scorpions, cicadas and leeches. The compound, whose name means “to open the network of the heart,” has long been used as a traditional Chinese treatment for patients who have had heart attacks and/or strokes.

    Based on promising results in cellular and animal models, the State Food and Drug Administration of China approved its use for the treatment of stroke and angina pectoris—a heart condition characterized by reoccurring chest pain—in 1996.

    But the medicine had never been evaluated in a randomized, double-blind, placebo-controlled clinical trial—the gold standard of drug testing that is usually required to approve treatments in the United States and Europe.

    The latest study, which has been published in JAMA (formerly The Journal of the American Medical Association), represents one of the first times that a traditional Chinese medicine has been tested in a large-scale, Western-style clinical trial.

    The authors of the study, who include researchers from several Chinese universities and hospitals, in collaboration with experts from the University of Texas Southwestern Medical Center (UTSW)—found that tongxinluo reduced the risk of heart attacks (known as myocardial infarctions), deaths and other major cardiovascular complications for at least a year after a first heart attack.

    Matthew Saybolt, a cardiologist with the Hackensack Meridian Jersey Shore University Medical Center who was not involved in the latest study, told Newsweek that he found the latest research “compelling” after reviewing the paper.

    “I am not aware of any other large, well-run trials like this studying traditional Chinese medicine. This is a rarely run type of study, and I congratulate the authors for their work and publication in such a prestigious medical journal,” Saybolt said.

    The study involved 3,777 patients at 124 clinical centers in China who had suffered the most severe form of heart attack—known as ST-segment elevation myocardial infarction, or STEMI. This condition involves a blood clot that completely blocks a major vessel supplying the heart. The patients were enrolled from May 2019 to December 2020, with the last date of follow-up occurring in December 2021.

    The patients were treated within hours of symptom onset by surgical or chemical removal of the clot. While they received standard treatments over the next year—such as taking a daily aspirin or medications including beta blockers—half of the individuals were randomly selected to receive tongxinluo as well. The other half were given a placebo—designed to match the look, smell and taste of the traditional Chinese medicine—instead.

    Over the next year, the patients were followed to track the incidence of major adverse cardiac and cerebrovascular events (MACCEs), an umbrella term that covers cardiac death, repeat heart attacks (myocardial reinfarctions), stroke and emergency procedures to restore blood flow to the heart.

    The results showed that the incidence of MACCEs was around 30 percent lower in the group that took tongxinluo, compared with those participants taking the placebo at 30 days of follow-up. These benefits persisted for one year after discharge, and no major side effects were recorded, indicating that the medicine was safe to use, the authors found.

    A stock image shows a doctor prescribing medicine. A traditional Chinese medicine has been shown to be effective at reducing complications from a heart attack after a large-scale, clinical trial.
    iStock

    “Many drugs have failed to achieve effects as impressive as this traditional Chinese medicine,” Dr. Ying Xian, an author of the study who is at UTSW, said in a press release.

    Saybolt said the study was “well conducted,” with a large sample size that was “well powered” to measure the outcomes.

    “In this trial, there is clearly a benefit to patients treated with this Chinese medicine compound compared to placebo,” he said.

    He went on: “A reduction in death, reinfarction or complications after a STEMI is a very exciting finding. We have for some time been trying to bend the curve and improve mortality and complications after STEMI. Any new therapy, if safe, that can accomplish this would be very appealing to patients and physicians alike.”

    Saybolt said he also observed some weaknesses in the way the study was conducted, one of which was that the participants were entirely Chinese citizens and predominantly male.

    “Thus the findings may not be generalizable throughout the world or to women,” he said. “Furthermore, the patients were less frequently—compared to the United States, for example—treated with traditional proven medicine after their myocardial infarctions. Therefore, the effect of the Chinese medicine may have been augmented by the lack of patient exposure to proven therapies.

    “However, there was equivalent low utilization of these traditional medications in both groups,” he continued. “Furthermore, the study drug Chinese medicine compound was composed of multiple plant and insect products. Thus, we do not know which component or combination of components were the active ingredients and what is the correct dose.”

    Further research will be needed to address these matters, and the benefits shown in this study would need to be duplicated in other populations before the treatment could get approved by the U.S. Food and Drug Administration.

    Saybolt said he would be “very interested” to see another study of its kind in a broader population outside China. “We must also isolate the compound into its individual components and determine which of the components is the therapeutic ingredient.”

    Traditional Chinese medicines are seldom tested in large, randomized, placebo-controlled, blinded trials, he said.

    “The gap in research is due to a combination of bias in research towards traditional pharmaceuticals and due to funding. Large trials such as this require funding from federal agencies, grants or industry sponsorship. A generic medicine or nutritional/herbal/animal/insect compound has little financial backing in many cases,” he said.

    Eric Peterson, a senior author of the study who is at UTSW, advised and collaborated with the Chinese researchers. He told Newsweek: “Is the medicine ready for the West? No. Does it show interesting promise? Absolutely. And we should not discount it. We have shown that traditional Chinese medicines can be tested.”

    He continued: “There’s a little bit of disbelief when you just look at the ingredients that are in it. People in the West…we have our doubts. We felt similarly about some of the drugs that we had to treat malaria until we found that they were actually pretty powerful medicines. So I think there are a lot of natural cures that actually are based on some believable and truthful benefits.”